Karuna Therapeutics stock (US5011311096): Lilly takeover keeps KRTX trading near deal price

Karuna Therapeutics shares continue to trade close to Eli Lilly’s agreed cash takeover price on Nasdaq, with investors watching for the final steps toward closing the all-cash merger in the United States biopharma sector.

Karuna Therapeutics shares on the Nasdaq in the United States remain anchored near the agreed Eli Lilly & Co. cash offer of USD 330.00 per share, with the stock recently changing hands at around USD 329 on the home exchange, according to Nasdaq price data as of 05/28/2026.

The all-cash acquisition by Eli Lilly, first announced in December 2023, values Karuna Therapeutics at roughly USD 14 billion and turned the clinical-stage neurology specialist into a strategic bolt-on for one of the largest US pharmaceutical groups, according to the original Eli Lilly press release as of 12/22/2023.

At the time of the announcement, the boards of both companies approved the transaction, which is structured as an all-cash tender offer followed by a merger, and Karuna Therapeutics indicated that shareholders would receive USD 330.00 per share in cash upon closing, according to the company’s investor relations statement as of 12/22/2023.

Regulatory approvals have been progressing since then, with Karuna Therapeutics filing relevant merger documentation with the US Securities and Exchange Commission (SEC), including a Schedule 14D-9 recommending that shareholders tender their shares into the Lilly offer, according to SEC filings as of early 2024 on sec.gov as of 01/12/2024.

While the stock now trades with limited volatility given the tight spread to the offer price, the situation remains relevant for US healthcare and biotech investors because completion of the deal will remove Karuna Therapeutics from standalone trading on the Nasdaq and consolidate its psychiatric pipeline within Eli Lilly’s broader neuroscience portfolio, according to transaction commentary from Reuters as of 12/22/2023.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Karuna Therapeutics
• Sector/industry: Biopharmaceuticals / neuroscience
• Headquarters/country: Boston, United States
• Core markets: United States and other major pharmaceutical markets
• Key revenue drivers: Future commercialization of psychiatric and neurological therapies, including schizophrenia treatment candidates
• Home exchange/listing venue: Nasdaq (KRTX)
• Trading currency: USD

Karuna Therapeutics: core business model

Karuna Therapeutics focuses on developing novel therapies for neuropsychiatric conditions, with value creation centered on advancing late-stage drug candidates for schizophrenia and related central nervous system disorders through clinical milestones and potential commercialization partnerships.

Pending transaction: Eli Lilly offer of USD 330.00 per share, expected close pending final conditions

Under the signed merger agreement, Eli Lilly offered Karuna Therapeutics shareholders USD 330.00 per share in cash, which represented a significant premium to the pre-deal trading price and was positioned as a way to strengthen Lilly’s position in psychiatry and neuroscience, according to the joint transaction announcement as of 12/22/2023.

The companies highlighted KarXT, Karuna Therapeutics’ lead investigational therapy for schizophrenia, as a key strategic asset in the deal, noting pivotal trial results and the potential to address an area of high unmet medical need in the United States and globally, based on details in Karuna’s Phase 3 results release as of 08/08/2023.

Valuation metrics and multiples for Karuna Therapeutics

Because Karuna Therapeutics is subject to a binding all-cash merger agreement with Eli Lilly at USD 330.00 per share, traditional valuation metrics such as price/earnings and EV/EBITDA have become less central for market participants, with the stock effectively valuing the company on the agreed takeout terms rather than on standalone trading multiples, according to Nasdaq and investor-relations data as of 05/28/2026.

Before the transaction announcement, Karuna Therapeutics, as a clinical-stage biopharmaceutical company without approved products, tended to trade on pipeline expectations and deal speculation rather than conventional earnings-based ratios, and investors often referenced the implied enterprise value of the Lilly offer of roughly USD 14 billion relative to the potential commercial opportunity for KarXT and other pipeline assets, based on estimates cited in coverage by Reuters as of 12/22/2023.

Conclusion

Karuna Therapeutics’ stock on the Nasdaq in the United States is effectively pinned to Eli Lilly’s USD 330.00 per share cash offer, with recent trading only marginally below the agreed consideration and reflecting residual deal risk and timing. For equity investors, the profile has shifted from a high-volatility clinical-stage biopharma story to a largely event-driven situation where the key variables are regulatory clearances, final closing conditions, and the treatment of neuropsychiatric assets within Lilly’s broader portfolio once the transaction completes. The valuation context now centers on the takeout price rather than on Karuna Therapeutics’ standalone earnings or pipeline metrics, which may still influence debate about how strategically accretive the acquisition will be for Eli Lilly in the long term.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.